image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Annual report which provides a comprehensive overview of the company for the past year

10-K EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Initial filing by director officer or owner of more than ten percent.

3 View HTML

Data provided by Kaleidoscope.